Test Bank Complete_
Clayton’s Basic Pharmacology For Nurses 19th Edition, (2022)
By Michelle J. Willihnganz, Samuel L. Gurevitz & Bruce D. Clayton
All Chapters 1-48| 8 Units| 2025/2026 Updated Edition With All Verified Answers| Grade A+
From: [Bestmaxsolutions.stuvia
,UNIT 1: APPLYING PHARMACOLOGY TO NURSING PRACTICE -------------------------------------------- 4
CHAPTER 01: DRUG DEFINITIONS, STANDARDS, AND INFORMATION SOURCES ----------------------------4
CHAPTER 02: BASIC PRINCIPLES OF DRUG ACTION AND DRUG INTERACTIONS --------------------------- 13
CHAPTER 03: DRUG ACTION ACROSS THE LIFE SPAN ------------------------------------------------------------- 24
CHAPTER 04: THE NURSINGPROCESS AND PHARMACOLOGY -------------------------------------------------- 37
CHAPTER 05: PATIENT EDUCATION TO PROMOTE HEALTH ----------------------------------------------------- 52
UNIT 2: ILLUSTRATED ATLAS OF MEDICATION ADMINISTRATION ------------------------------------ 64
CHAPTER 06: PRINCIPLES OF MEDICATION ADMINISTRATION AND MEDICATION SAFETY ------------- 64
CHAPTER 07: PERCUTANEOUS ADMINISTRATION ----------------------------------------------------------------- 78
CHAPTER 08: ENTERAL ADMINISTRATION --------------------------------------------------------------------------- 91
CHAPTER 09: PARENTERAL ADMINISTRATION: SAFE PREPARATION OF PARENTERAL MEDICATIONS
-------------------------------------------------------------------------------------------------------------------------------- 102
CHAPTER 10: PARENTERAL ADMINISTRATION: INTRADERMAL, SUBCUTANEOUS, AND
INTRAMUSCULAR ROUTES --------------------------------------------------------------------------------------------- 113
CHAPTER 11: PARENTERAL ADMINISTRATION: INTRAVENOUS ROUTE ------------------------------------ 125
UNIT 3: DRUGS AFFECTING THE AUTONOMIC AND CENTRAL NERVOUS SYSTEMS ------------- 138
CHAPTER 12: DRUGS AFFECTING THE AUTONOMIC NERVOUS SYSTEM ----------------------------------- 138
CHAPTER 13: DRUGS USED FOR SEDATION AND SLEEP -------------------------------------------------------- 153
CHAPTER 14: DRUGS USED TO TREAT NEURODEGENERATIVE DISORDERS ------------------------------- 165
CHAPTER 15: DRUGS USED FOR ANXIETY DISORDERS ---------------------------------------------------------- 175
CHAPTER 16: DRUGS USED FOR DEPRESSIVE AND BIPOLAR DISORDERS ---------------------------------- 187
CHAPTER 17: DRUGS USED FOR PSYCHOSES ---------------------------------------------------------------------- 203
CHAPTER 18: DRUGS USED FOR SEIZURE DISORDERS ---------------------------------------------------------- 215
CHAPTER 19: DRUGS USED FOR PAIN MANAGEMENT --------------------------------------------------------- 227
UNIT 4: DRUGS AFFECTING THE CARDIOVASCULAR SYSTEM ----------------------------------------- 241
CHAPTER 20: INTRODUCTION TO CARDIOVASCULAR DISEASE AND METABOLIC SYNDROME ------- 241
CHAPTER 21: DRUGS USED TO TREAT DYSLIPIDEMIAS --------------------------------------------------------- 250
CHAPTER 22: DRUGS USED TO TREAT HYPERTENSION --------------------------------------------------------- 263
CHAPTER 23: DRUGS USED TO TREAT DYSRHYTHMIAS -------------------------------------------------------- 280
CHAPTER 24: DRUGS USED TO TREAT ANGINA PECTORIS ----------------------------------------------------- 290
CHAPTER 25: DRUGS USED TO TREAT PERIPHERAL VASCULAR DISEASE----------------------------------- 305
CHAPTER 26: DRUGS USED TO TREAT THROMBOEMBOLIC DISORDERS ----------------------------------- 314
, CHAPTER 27: DRUGS USED TO TREAT HEART FAILURE --------------------------------------------------------- 327
CHAPTER 28: DRUGS USED FOR DIURESIS ------------------------------------------------------------------------- 340
UNIT 5: DRUGS AFFECTING THE RESPIRATORY SYSTEM ----------------------------------------------- 353
CHAPTER 29: DRUGS USED TO TREAT UPPER RESPIRATORY DISEASE -------------------------------------- 353
CHAPTER 30: DRUGS USED TO TREAT LOWER RESPIRATORY DISEASE ------------------------------------- 365
UNIT 6: DRUGS AFFECTING THE DIGESTIVE SYSTEM ---------------------------------------------------- 382
CHAPTER 31: DRUGS USED TO TREAT ORAL DISORDERS ------------------------------------------------------ 382
CHAPTER 32: DRUGS USED TO TREAT GASTROESOPHAGEAL REFLUX AND PEPTIC ULCER DISEASE 394
CHAPTER 33: DRUGS USED TO TREAT NAUSEA AND VOMITING --------------------------------------------- 407
CHAPTER 34: DRUGS USED TO TREAT CONSTIPATION AND DIARRHEA ------------------------------------ 418
UNIT 7: DRUGS THAT AFFECT THE ENDOCRINE SYSTEM ----------------------------------------------- 431
CHAPTER 35: DRUGS USED TO TREAT DIABETES MELLITUS --------------------------------------------------- 431
CHAPTER 36: DRUGS USED TO TREAT THYROID DISEASE ------------------------------------------------------ 445
CHAPTER 37: CORTICOSTEROIDS ------------------------------------------------------------------------------------- 456
CHAPTER 38: GONADAL HORMONES ------------------------------------------------------------------------------- 469
UNIT 8: DRUGS AFFECTING THE REPRODUCTIVE SYSTEM --------------------------------------------- 481
CHAPTER 39: DRUGS USED IN OBSTETRICS ------------------------------------------------------------------------ 481
CHAPTER 40: DRUGS USED IN MEN’S AND WOMEN’S HEALTH ---------------------------------------------- 493
CHAPTER 41: DRUGS USED TO TREAT DISORDERS OF THE URINARY SYSTEM ---------------------------- 505
CHAPTER 42: DRUGS USED TO TREAT GLAUCOMA AND OTHER EYE DISORDERS ----------------------- 517
CHAPTER 43: DRUGS USED TO TREAT CANCER ------------------------------------------------------------------- 529
CHAPTER 44: DRUGS USED TO TREAT THE MUSCULOSKELETAL SYSTEM ---------------------------------- 541
CHAPTER 45: DRUGS USED TO TREAT INFECTIONS -------------------------------------------------------------- 553
CHAPTER 46: NUTRITION ----------------------------------------------------------------------------------------------- 564
CHAPTER 47: HERBAL AND DIETARY SUPPLEMENT THERAPY ------------------------------------------------ 574
CHAPTER 48: SUBSTANCE ABUSE ------------------------------------------------------------------------------------ 585
,UNIT 1: APPLYING PHARMACOLOGY TO NURSING PRACTICE
CHAPTER 01: DRUG DEFINITIONS, STANDARDS, AND INFORMATION SOURCES
Michelle J. Willihnganz: Clayton’s Basic Pharmacology for Nurses 19th Edition, (2022) Test Bank
MULTIPLE CHOICE
1. WHAT IS THE NAME UNDER WHICH A DRUG IS LISTED BY THE US FOOD AND DRUG
ADMINISTRATION (FDA)?
A. BRAND
B. NONPROPRIETARY
C. OFFICIAL
D. TRADEMARK
ANS: C
THE OFFICIAL NAME IS THE NAME UNDER WHICH A DRUG IS LISTED BY THE FDA. THE
BRAND NAME, OR TRADEMARK, IS THE NAME GIVEN TO A DRUG BY ITS MANUFACTURER.
THE NONPROPRIETARY, OR GENERIC, NAME IS PROVIDED BY THE UNITED STATES
ADOPTED NAMES COUNCIL.
DIF: COGNITIVE LEVEL: KNOWLEDGE REF: P. 2
OBJ: 1 NAT: NCLEXCLIENT NEEDSCATEGORY: SAFE, EFFECTIVE CARE ENVIRONMENT
TOP: NURSINGPROCESS STEP: ASSESSMENT CON: PATIENT EDUCATION
2. WHICH SOURCE CONTAINS INFORMATION SPECIFIC TO NUTRITIONAL SUPPLEMENTS?
A. USP DICTIONARY OF USAN & INTERNATIONAL DRUG NAMES
B. NATURAL MEDICINES COMPREHENSIVE DATABASE
C. UNITED STATES PHARMACOPOEIA/NATIONAL FORMULARY (USP NF)
D. DRUG INTERACTION FACTS
ANS: C
UNITED STATES PHARMACOPOEIA/NATIONAL FORMULARY CONTAINS INFORMATION
SPECIFIC TO NUTRITIONAL SUPPLEMENTS. USP DICTIONARY OF USAN & INTERNATIONAL
DRUG NAMES IS A COMPILATION OF DRUG NAMES, PRONUNCIATION GUIDE, AND
POSSIBLE FUTURE FDA APPROVED DRUGS; IT DOES NOT INCLUDE NUTRITIONAL
SUPPLEMENTS. NATURAL MEDICINES COMPREHENSIVE DATABASE CONTAINS EVIDENCE-
BASED INFORMATION ON HERBAL MEDICINES AND HERBAL COMBINATION PRODUCTS; IT
,DOES NOT INCLUDE INFORMATION SPECIFIC TO NUTRITIONAL SUPPLEMENTS. DRUG
INTERACTION FACTS CONTAINS COMPREHENSIVE INFORMATION ON DRUG INTERACTION
FACTS; IT DOES NOT INCLUDE NUTRITIONAL SUPPLEMENTS.
DIF: COGNITIVE LEVEL: KNOWLEDGE REF: P. 2 | P. 3
OBJ: 3 NAT: NCLEXCLIENT NEEDSCATEGORY: PHYSIOLOGICAL INTEGRITY
TOP: NURSINGPROCESS STEP: ASSESSMENT CON: NUTRITION | PATIENT EDUCATION
3. WHAT IS THE MOST COMPREHENSIVE REFERENCE AVAILABLE TO RESEARCH A DRUG
INTERACTION?
A. DRUG FACTS AND COMPARISONS
B. DRUG INTERACTION FACTS
C. HANDBOOK ON INJECTABLE DRUGS
D. MARTINDALE—THE COMPLETE DRUG REFERENCE
ANS: B
FIRST PUBLISHED IN 1983, DRUG INTERACTION FACTS IS THE MOST COMPREHENSIVE
BOOK AVAILABLE ON DRUG INTERACTIONS. IN ADDITION TO MONOGRAPHS LISTING
VARIOUS ASPECTS OF DRUG INTERACTIONS, THIS INFORMATION IS REVIEWED AND
UPDATED BY AN INTERNATIONALLY RENOWNED GROUP OF PHYSICIANS AND
PHARMACISTS WITH CLINICAL AND SCIENTIFIC EXPERTISE.
DIF: COGNITIVE LEVEL: COMPREHENSION REF: P. 4
OBJ: 3 NAT: NCLEXCLIENT NEEDSCATEGORY: PHYSIOLOGICAL INTEGRITY
TOP: NURSINGPROCESS STEP: ASSESSMENT CON: SAFETY | PATIENT EDUCATION |
CLINICAL JUDGMENT
4. THE PHYSICIAN HAS WRITTEN AN ORDER FOR A DRUG WITH WHICH THE NURSE IS
UNFAMILIAR. WHICH SECTION OF THE PHYSICIANS’ DESK REFERENCE (PDR) IS MOST
HELPFUL TO GET INFORMATION ABOUT THIS DRUG?
A. MANUFACTURER ‘S SECTION
B. BRAND AND GENERIC NAME SECTION
C. PRODUCT CATEGORY SECTION
D. PRODUCT INFORMATION SECTION
ANS: B
A PHYSICIAN ‘S ORDER WOULD INCLUDE THE BRAND AND/OR GENERIC NAME OF THE
DRUG. THE ALPHABETIC INDEX IN THE PDR WOULD MAKE THIS SECTION THE MOST
USER-FRIENDLY. BASED ON A PHYSICIAN‘S ORDER, MANUFACTURER‘S INFORMATION
,AND CLASSIFICATION INFORMATION WOULD NOT BE KNOWN. THE MANUFACTURER ‘S
SECTION IS A ROSTER OF MANUFACTURERS. THE PRODUCT CATEGORY SECTION LISTS
PRODUCTS SUBDIVIDED BY THERAPEUTIC CLASSES, SUCH AS ANALGESICS, LAXATIVES,
OXYTOCICS, AND ANTIBIOTICS. THE PRODUCT INFORMATION SECTION CONTAINS
REPRINTS OF THE PACKAGE INSERTS FOR THE MAJOR PRODUCTS OF MANUFACTURERS.
DIF: COGNITIVE LEVEL: COMPREHENSION REF: P. 4
OBJ: 3 NAT: NCLEXCLIENT NEEDSCATEGORY: PHYSIOLOGICAL INTEGRITY
TOP: NURSINGPROCESS STEP: PLANNING CON: SAFETY | PATIENT EDUCATION |
CLINICAL JUDGMENT
5. WHICH ONLINE DRUG REFERENCE MAKES AVAILABLE TO HEALTHCARE PROVIDERS
AND THE PUBLIC A STANDARD, COMPREHENSIVE, UP-TO-DATE LOOK UP AND
DOWNLOADABLE RESOURCE ABOUT MEDICINES?
A. AMERICAN DRUG INDEX
B. AMERICAN HOSPITAL FORMULARY
C. DAILYMED
D. PHYSICIANS’ DESK REFERENCE (PDR)
ANS: C
DAILYMED MAKES AVAILABLE TO HEALTHCARE PROVIDERS AND THE PUBLIC A
STANDARD, COMPREHENSIVE, UP- TO-DATE LOOK UP AND DOWNLOADABLE RESOURCE
ABOUT MEDICINES. THE AMERICAN DRUG INDEX IS NOT APPROPRIATE FOR PATIENT USE.
THE AMERICAN HOSPITAL FORMULARY IS NOT APPROPRIATE FOR PATIENT USE. THE PDR
IS NOT APPROPRIATE FOR PATIENT USE.
DIF: COGNITIVE LEVEL: KNOWLEDGE REF: P. 3 | P. 5 OBJ: 4 NAT: NCLEXCLIENT
NEEDSCATEGORY: PHYSIOLOGICAL INTEGRITY TOP: NURSINGPROCESS STEP:
IMPLEMENTATION
CON: SAFETY | PATIENT EDUCATION | CLINICAL JUDGMENT
6. WHICH LEGISLATION AUTHORIZES THE FDA TO DETERMINE THE SAFETY OF A DRUG
BEFORE ITS MARKETING?
A. FEDERAL FOOD, DRUG, AND COSMETIC ACT (1938)
B. DURHAM HUMPHREY AMENDMENT (1952)
C. CONTROLLED SUBSTANCES ACT (1970)
D. KEFAUVER HARRIS DRUG AMENDMENT (1962)
ANS: A
,THE FEDERAL FOOD, DRUG, AND COSMETIC ACT OF 1938 AUTHORIZED THE FDA TO
DETERMINE THE SAFETY OF ALL DRUGS BEFORE MARKETING. LATER AMENDMENTS AND
ACTS HELPED TIGHTEN FDA CONTROL AND ENSURE DRUG SAFETY. THE DURHAM
HUMPHREY AMENDMENT DEFINES THE KINDS OF DRUGS THAT CANNOT BE USED SAFELY
WITHOUT MEDICAL SUPERVISION AND RESTRICTS THEIR SALE TO PRESCRIPTION BY A
LICENSED PRACTITIONER. THE CONTROLLED SUBSTANCES ACT ADDRESSES ONLY
CONTROLLED SUBSTANCES AND THEIR CATEGORIZATION. THE KEFAUVER HARRIS DRUG
AMENDMENT ENSURES DRUG EFFICACY AND GREATER DRUG SAFETY. DRUG
MANUFACTURERS ARE REQUIRED TO PROVE TO THE FDA THE EFFECTIVENESS OF THEIR
PRODUCTS BEFORE MARKETING THEM.
DIF: COGNITIVE LEVEL: KNOWLEDGE REF: P. 5 OBJ: 6 NAT: NCLEXCLIENT
NEEDSCATEGORY: PHYSIOLOGICAL INTEGRITY TOP: NURSINGPROCESS STEP: ASSESSMENT
CON: SAFETY | PATIENT EDUCATION | EVIDENCE | HEALTH CARE LAW
7. MEPERIDINE (DEMEROL) IS A NARCOTIC WITH A HIGH POTENTIAL FOR PHYSICAL AND
PSYCHOLOGICAL DEPENDENCY. UNDER WHICH CLASSIFICATION DOES THIS DRUG FALL?
A. I
B. II
C. III
D. IV
ANS: B
MEPERIDINE (DEMEROL) IS A SCHEDULE II DRUG; IT HAS A HIGH POTENTIAL FOR ABUSE
AND MAY LEAD TO SEVERE PSYCHOLOGICAL AND PHYSICAL DEPENDENCE. SCHEDULE I
DRUGS HAVE HIGH POTENTIAL FOR ABUSE AND NO RECOGNIZED MEDICAL USE.
SCHEDULE III DRUGS HAVE SOME POTENTIAL FOR ABUSE. USE MAY LEAD TO LOW TO
MODERATE PHYSICAL DEPENDENCE OR HIGH PSYCHOLOGICAL DEPENDENCE. SCHEDULE
IV DRUGS HAVE LOW POTENTIAL FOR ABUSE. USE MAY LEAD TO LIMITED PHYSICAL OR
PSYCHOLOGICAL DEPENDENCE.
DIF: COGNITIVE LEVEL: COMPREHENSION REF: P. 5 OBJ: 2 NAT: NCLEXCLIENT
NEEDSCATEGORY: SAFE, EFFECTIVE CARE ENVIRONMENT TOP: NURSINGPROCESS STEP:
ASSESSMENT CON: PATIENT EDUCATION | ADDICTION | PAIN
8. WHAT WOULD THE FDA DO TO EXPEDITE DRUG DEVELOPMENT AND APPROVAL FOR
AN OUTBREAK OF SMALLPOX, FOR WHICH THERE IS NO KNOWN TREATMENT?
A. LIST SMALLPOX AS A HEALTH ORPHAN DISEASE.
B. OMIT THE PRECLINICAL RESEARCH PHASE.
, C. EXTEND THE CLINICAL RESEARCH PHASE.
D. FAST TRACK THE INVESTIGATIONAL DRUG.
ANS: D
ONCE THE INVESTIGATIONAL NEW DRUG APPLICATION HAS BEEN APPROVED, THE DRUG
CAN RECEIVE HIGHEST PRIORITY WITHIN THE AGENCY, WHICH IS CALLED FAST
TRACKING. A SMALLPOX OUTBREAK WOULD BECOME A PRIORITY CONCERN IN THE
WORLD. ORPHAN DISEASES ARE NOT RESEARCHED IN A PRIORITY MANNER.
PRECLINICAL RESEARCH IS NOT OMITTED. EXTENDING ANY PHASE OF THE RESEARCH
WOULD MEAN A LONGER TIME TO DEVELOP A VACCINE. THE FDA MUST ENSURE THAT
ALL PHASES OF THE PRECLINICAL AND CLINICAL RESEARCH PHASE HAVE BEEN
COMPLETED IN A SAFE MANNER.
DIF: COGNITIVE LEVEL: KNOWLEDGE REF: P. 8 OBJ: 6 NAT: NCLEXCLIENT
NEEDSCATEGORY: SAFE, EFFECTIVE CARE ENVIRONMENT TOP: NURSINGPROCESS STEP:
ASSESSMENT
CON: HEALTH CARE LAW | HEALTH CARE POLICY | INFECTION | CARE COORDINATION
9. WHICH STATEMENT IS TRUE ABOUT OVER-THE-COUNTER (OTC) DRUGS?
A. THEY ARE NOT LISTED IN THE USP NF.
B. A PRESCRIPTION FROM A HEALTHCARE PROVIDER IS NEEDED.
C. THEY ARE SOLD WITHOUT A PRESCRIPTION.
D. THEY ARE KNOWN ONLY BY THEIR BRAND NAMES.
ANS: C
OTC MEDICATIONS DO NOT REQUIRE A PRESCRIPTION. A VARIETY OF NAMES, BOTH
GENERIC AND TRADE, CAN BE USED FOR INDIVIDUAL DRUGS SOLD OTC. OTC DRUGS ARE
LISTED IN THE USP NF. PRESCRIPTION DRUGS REQUIRE AN ORDER BY A HEALTH
PROFESSIONAL WHO IS LICENSED TO PRESCRIBE, SUCH AS A PHYSICIAN, NURSE
PRACTITIONER, PHYSICIAN ASSISTANT, OR DENTIST.
DIF: COGNITIVE LEVEL: COMPREHENSION REF: P. 2 OBJ: 2 NAT:
NCLEXCLIENT NEEDSCATEGORY: PHYSIOLOGICAL INTEGRITY TOP: NURSINGPROCESS STEP:
PLANNING CON: PATIENT EDUCATION
10. WHICH IS THE MOST AUTHORITATIVE REFERENCE FOR MEDICATIONS THAT ARE
INJECTED?
A. PHYSICIANS’ DESK REFERENCE
B. HANDBOOK ON INJECTABLE DRUGS
Clayton’s Basic Pharmacology For Nurses 19th Edition, (2022)
By Michelle J. Willihnganz, Samuel L. Gurevitz & Bruce D. Clayton
All Chapters 1-48| 8 Units| 2025/2026 Updated Edition With All Verified Answers| Grade A+
From: [Bestmaxsolutions.stuvia
,UNIT 1: APPLYING PHARMACOLOGY TO NURSING PRACTICE -------------------------------------------- 4
CHAPTER 01: DRUG DEFINITIONS, STANDARDS, AND INFORMATION SOURCES ----------------------------4
CHAPTER 02: BASIC PRINCIPLES OF DRUG ACTION AND DRUG INTERACTIONS --------------------------- 13
CHAPTER 03: DRUG ACTION ACROSS THE LIFE SPAN ------------------------------------------------------------- 24
CHAPTER 04: THE NURSINGPROCESS AND PHARMACOLOGY -------------------------------------------------- 37
CHAPTER 05: PATIENT EDUCATION TO PROMOTE HEALTH ----------------------------------------------------- 52
UNIT 2: ILLUSTRATED ATLAS OF MEDICATION ADMINISTRATION ------------------------------------ 64
CHAPTER 06: PRINCIPLES OF MEDICATION ADMINISTRATION AND MEDICATION SAFETY ------------- 64
CHAPTER 07: PERCUTANEOUS ADMINISTRATION ----------------------------------------------------------------- 78
CHAPTER 08: ENTERAL ADMINISTRATION --------------------------------------------------------------------------- 91
CHAPTER 09: PARENTERAL ADMINISTRATION: SAFE PREPARATION OF PARENTERAL MEDICATIONS
-------------------------------------------------------------------------------------------------------------------------------- 102
CHAPTER 10: PARENTERAL ADMINISTRATION: INTRADERMAL, SUBCUTANEOUS, AND
INTRAMUSCULAR ROUTES --------------------------------------------------------------------------------------------- 113
CHAPTER 11: PARENTERAL ADMINISTRATION: INTRAVENOUS ROUTE ------------------------------------ 125
UNIT 3: DRUGS AFFECTING THE AUTONOMIC AND CENTRAL NERVOUS SYSTEMS ------------- 138
CHAPTER 12: DRUGS AFFECTING THE AUTONOMIC NERVOUS SYSTEM ----------------------------------- 138
CHAPTER 13: DRUGS USED FOR SEDATION AND SLEEP -------------------------------------------------------- 153
CHAPTER 14: DRUGS USED TO TREAT NEURODEGENERATIVE DISORDERS ------------------------------- 165
CHAPTER 15: DRUGS USED FOR ANXIETY DISORDERS ---------------------------------------------------------- 175
CHAPTER 16: DRUGS USED FOR DEPRESSIVE AND BIPOLAR DISORDERS ---------------------------------- 187
CHAPTER 17: DRUGS USED FOR PSYCHOSES ---------------------------------------------------------------------- 203
CHAPTER 18: DRUGS USED FOR SEIZURE DISORDERS ---------------------------------------------------------- 215
CHAPTER 19: DRUGS USED FOR PAIN MANAGEMENT --------------------------------------------------------- 227
UNIT 4: DRUGS AFFECTING THE CARDIOVASCULAR SYSTEM ----------------------------------------- 241
CHAPTER 20: INTRODUCTION TO CARDIOVASCULAR DISEASE AND METABOLIC SYNDROME ------- 241
CHAPTER 21: DRUGS USED TO TREAT DYSLIPIDEMIAS --------------------------------------------------------- 250
CHAPTER 22: DRUGS USED TO TREAT HYPERTENSION --------------------------------------------------------- 263
CHAPTER 23: DRUGS USED TO TREAT DYSRHYTHMIAS -------------------------------------------------------- 280
CHAPTER 24: DRUGS USED TO TREAT ANGINA PECTORIS ----------------------------------------------------- 290
CHAPTER 25: DRUGS USED TO TREAT PERIPHERAL VASCULAR DISEASE----------------------------------- 305
CHAPTER 26: DRUGS USED TO TREAT THROMBOEMBOLIC DISORDERS ----------------------------------- 314
, CHAPTER 27: DRUGS USED TO TREAT HEART FAILURE --------------------------------------------------------- 327
CHAPTER 28: DRUGS USED FOR DIURESIS ------------------------------------------------------------------------- 340
UNIT 5: DRUGS AFFECTING THE RESPIRATORY SYSTEM ----------------------------------------------- 353
CHAPTER 29: DRUGS USED TO TREAT UPPER RESPIRATORY DISEASE -------------------------------------- 353
CHAPTER 30: DRUGS USED TO TREAT LOWER RESPIRATORY DISEASE ------------------------------------- 365
UNIT 6: DRUGS AFFECTING THE DIGESTIVE SYSTEM ---------------------------------------------------- 382
CHAPTER 31: DRUGS USED TO TREAT ORAL DISORDERS ------------------------------------------------------ 382
CHAPTER 32: DRUGS USED TO TREAT GASTROESOPHAGEAL REFLUX AND PEPTIC ULCER DISEASE 394
CHAPTER 33: DRUGS USED TO TREAT NAUSEA AND VOMITING --------------------------------------------- 407
CHAPTER 34: DRUGS USED TO TREAT CONSTIPATION AND DIARRHEA ------------------------------------ 418
UNIT 7: DRUGS THAT AFFECT THE ENDOCRINE SYSTEM ----------------------------------------------- 431
CHAPTER 35: DRUGS USED TO TREAT DIABETES MELLITUS --------------------------------------------------- 431
CHAPTER 36: DRUGS USED TO TREAT THYROID DISEASE ------------------------------------------------------ 445
CHAPTER 37: CORTICOSTEROIDS ------------------------------------------------------------------------------------- 456
CHAPTER 38: GONADAL HORMONES ------------------------------------------------------------------------------- 469
UNIT 8: DRUGS AFFECTING THE REPRODUCTIVE SYSTEM --------------------------------------------- 481
CHAPTER 39: DRUGS USED IN OBSTETRICS ------------------------------------------------------------------------ 481
CHAPTER 40: DRUGS USED IN MEN’S AND WOMEN’S HEALTH ---------------------------------------------- 493
CHAPTER 41: DRUGS USED TO TREAT DISORDERS OF THE URINARY SYSTEM ---------------------------- 505
CHAPTER 42: DRUGS USED TO TREAT GLAUCOMA AND OTHER EYE DISORDERS ----------------------- 517
CHAPTER 43: DRUGS USED TO TREAT CANCER ------------------------------------------------------------------- 529
CHAPTER 44: DRUGS USED TO TREAT THE MUSCULOSKELETAL SYSTEM ---------------------------------- 541
CHAPTER 45: DRUGS USED TO TREAT INFECTIONS -------------------------------------------------------------- 553
CHAPTER 46: NUTRITION ----------------------------------------------------------------------------------------------- 564
CHAPTER 47: HERBAL AND DIETARY SUPPLEMENT THERAPY ------------------------------------------------ 574
CHAPTER 48: SUBSTANCE ABUSE ------------------------------------------------------------------------------------ 585
,UNIT 1: APPLYING PHARMACOLOGY TO NURSING PRACTICE
CHAPTER 01: DRUG DEFINITIONS, STANDARDS, AND INFORMATION SOURCES
Michelle J. Willihnganz: Clayton’s Basic Pharmacology for Nurses 19th Edition, (2022) Test Bank
MULTIPLE CHOICE
1. WHAT IS THE NAME UNDER WHICH A DRUG IS LISTED BY THE US FOOD AND DRUG
ADMINISTRATION (FDA)?
A. BRAND
B. NONPROPRIETARY
C. OFFICIAL
D. TRADEMARK
ANS: C
THE OFFICIAL NAME IS THE NAME UNDER WHICH A DRUG IS LISTED BY THE FDA. THE
BRAND NAME, OR TRADEMARK, IS THE NAME GIVEN TO A DRUG BY ITS MANUFACTURER.
THE NONPROPRIETARY, OR GENERIC, NAME IS PROVIDED BY THE UNITED STATES
ADOPTED NAMES COUNCIL.
DIF: COGNITIVE LEVEL: KNOWLEDGE REF: P. 2
OBJ: 1 NAT: NCLEXCLIENT NEEDSCATEGORY: SAFE, EFFECTIVE CARE ENVIRONMENT
TOP: NURSINGPROCESS STEP: ASSESSMENT CON: PATIENT EDUCATION
2. WHICH SOURCE CONTAINS INFORMATION SPECIFIC TO NUTRITIONAL SUPPLEMENTS?
A. USP DICTIONARY OF USAN & INTERNATIONAL DRUG NAMES
B. NATURAL MEDICINES COMPREHENSIVE DATABASE
C. UNITED STATES PHARMACOPOEIA/NATIONAL FORMULARY (USP NF)
D. DRUG INTERACTION FACTS
ANS: C
UNITED STATES PHARMACOPOEIA/NATIONAL FORMULARY CONTAINS INFORMATION
SPECIFIC TO NUTRITIONAL SUPPLEMENTS. USP DICTIONARY OF USAN & INTERNATIONAL
DRUG NAMES IS A COMPILATION OF DRUG NAMES, PRONUNCIATION GUIDE, AND
POSSIBLE FUTURE FDA APPROVED DRUGS; IT DOES NOT INCLUDE NUTRITIONAL
SUPPLEMENTS. NATURAL MEDICINES COMPREHENSIVE DATABASE CONTAINS EVIDENCE-
BASED INFORMATION ON HERBAL MEDICINES AND HERBAL COMBINATION PRODUCTS; IT
,DOES NOT INCLUDE INFORMATION SPECIFIC TO NUTRITIONAL SUPPLEMENTS. DRUG
INTERACTION FACTS CONTAINS COMPREHENSIVE INFORMATION ON DRUG INTERACTION
FACTS; IT DOES NOT INCLUDE NUTRITIONAL SUPPLEMENTS.
DIF: COGNITIVE LEVEL: KNOWLEDGE REF: P. 2 | P. 3
OBJ: 3 NAT: NCLEXCLIENT NEEDSCATEGORY: PHYSIOLOGICAL INTEGRITY
TOP: NURSINGPROCESS STEP: ASSESSMENT CON: NUTRITION | PATIENT EDUCATION
3. WHAT IS THE MOST COMPREHENSIVE REFERENCE AVAILABLE TO RESEARCH A DRUG
INTERACTION?
A. DRUG FACTS AND COMPARISONS
B. DRUG INTERACTION FACTS
C. HANDBOOK ON INJECTABLE DRUGS
D. MARTINDALE—THE COMPLETE DRUG REFERENCE
ANS: B
FIRST PUBLISHED IN 1983, DRUG INTERACTION FACTS IS THE MOST COMPREHENSIVE
BOOK AVAILABLE ON DRUG INTERACTIONS. IN ADDITION TO MONOGRAPHS LISTING
VARIOUS ASPECTS OF DRUG INTERACTIONS, THIS INFORMATION IS REVIEWED AND
UPDATED BY AN INTERNATIONALLY RENOWNED GROUP OF PHYSICIANS AND
PHARMACISTS WITH CLINICAL AND SCIENTIFIC EXPERTISE.
DIF: COGNITIVE LEVEL: COMPREHENSION REF: P. 4
OBJ: 3 NAT: NCLEXCLIENT NEEDSCATEGORY: PHYSIOLOGICAL INTEGRITY
TOP: NURSINGPROCESS STEP: ASSESSMENT CON: SAFETY | PATIENT EDUCATION |
CLINICAL JUDGMENT
4. THE PHYSICIAN HAS WRITTEN AN ORDER FOR A DRUG WITH WHICH THE NURSE IS
UNFAMILIAR. WHICH SECTION OF THE PHYSICIANS’ DESK REFERENCE (PDR) IS MOST
HELPFUL TO GET INFORMATION ABOUT THIS DRUG?
A. MANUFACTURER ‘S SECTION
B. BRAND AND GENERIC NAME SECTION
C. PRODUCT CATEGORY SECTION
D. PRODUCT INFORMATION SECTION
ANS: B
A PHYSICIAN ‘S ORDER WOULD INCLUDE THE BRAND AND/OR GENERIC NAME OF THE
DRUG. THE ALPHABETIC INDEX IN THE PDR WOULD MAKE THIS SECTION THE MOST
USER-FRIENDLY. BASED ON A PHYSICIAN‘S ORDER, MANUFACTURER‘S INFORMATION
,AND CLASSIFICATION INFORMATION WOULD NOT BE KNOWN. THE MANUFACTURER ‘S
SECTION IS A ROSTER OF MANUFACTURERS. THE PRODUCT CATEGORY SECTION LISTS
PRODUCTS SUBDIVIDED BY THERAPEUTIC CLASSES, SUCH AS ANALGESICS, LAXATIVES,
OXYTOCICS, AND ANTIBIOTICS. THE PRODUCT INFORMATION SECTION CONTAINS
REPRINTS OF THE PACKAGE INSERTS FOR THE MAJOR PRODUCTS OF MANUFACTURERS.
DIF: COGNITIVE LEVEL: COMPREHENSION REF: P. 4
OBJ: 3 NAT: NCLEXCLIENT NEEDSCATEGORY: PHYSIOLOGICAL INTEGRITY
TOP: NURSINGPROCESS STEP: PLANNING CON: SAFETY | PATIENT EDUCATION |
CLINICAL JUDGMENT
5. WHICH ONLINE DRUG REFERENCE MAKES AVAILABLE TO HEALTHCARE PROVIDERS
AND THE PUBLIC A STANDARD, COMPREHENSIVE, UP-TO-DATE LOOK UP AND
DOWNLOADABLE RESOURCE ABOUT MEDICINES?
A. AMERICAN DRUG INDEX
B. AMERICAN HOSPITAL FORMULARY
C. DAILYMED
D. PHYSICIANS’ DESK REFERENCE (PDR)
ANS: C
DAILYMED MAKES AVAILABLE TO HEALTHCARE PROVIDERS AND THE PUBLIC A
STANDARD, COMPREHENSIVE, UP- TO-DATE LOOK UP AND DOWNLOADABLE RESOURCE
ABOUT MEDICINES. THE AMERICAN DRUG INDEX IS NOT APPROPRIATE FOR PATIENT USE.
THE AMERICAN HOSPITAL FORMULARY IS NOT APPROPRIATE FOR PATIENT USE. THE PDR
IS NOT APPROPRIATE FOR PATIENT USE.
DIF: COGNITIVE LEVEL: KNOWLEDGE REF: P. 3 | P. 5 OBJ: 4 NAT: NCLEXCLIENT
NEEDSCATEGORY: PHYSIOLOGICAL INTEGRITY TOP: NURSINGPROCESS STEP:
IMPLEMENTATION
CON: SAFETY | PATIENT EDUCATION | CLINICAL JUDGMENT
6. WHICH LEGISLATION AUTHORIZES THE FDA TO DETERMINE THE SAFETY OF A DRUG
BEFORE ITS MARKETING?
A. FEDERAL FOOD, DRUG, AND COSMETIC ACT (1938)
B. DURHAM HUMPHREY AMENDMENT (1952)
C. CONTROLLED SUBSTANCES ACT (1970)
D. KEFAUVER HARRIS DRUG AMENDMENT (1962)
ANS: A
,THE FEDERAL FOOD, DRUG, AND COSMETIC ACT OF 1938 AUTHORIZED THE FDA TO
DETERMINE THE SAFETY OF ALL DRUGS BEFORE MARKETING. LATER AMENDMENTS AND
ACTS HELPED TIGHTEN FDA CONTROL AND ENSURE DRUG SAFETY. THE DURHAM
HUMPHREY AMENDMENT DEFINES THE KINDS OF DRUGS THAT CANNOT BE USED SAFELY
WITHOUT MEDICAL SUPERVISION AND RESTRICTS THEIR SALE TO PRESCRIPTION BY A
LICENSED PRACTITIONER. THE CONTROLLED SUBSTANCES ACT ADDRESSES ONLY
CONTROLLED SUBSTANCES AND THEIR CATEGORIZATION. THE KEFAUVER HARRIS DRUG
AMENDMENT ENSURES DRUG EFFICACY AND GREATER DRUG SAFETY. DRUG
MANUFACTURERS ARE REQUIRED TO PROVE TO THE FDA THE EFFECTIVENESS OF THEIR
PRODUCTS BEFORE MARKETING THEM.
DIF: COGNITIVE LEVEL: KNOWLEDGE REF: P. 5 OBJ: 6 NAT: NCLEXCLIENT
NEEDSCATEGORY: PHYSIOLOGICAL INTEGRITY TOP: NURSINGPROCESS STEP: ASSESSMENT
CON: SAFETY | PATIENT EDUCATION | EVIDENCE | HEALTH CARE LAW
7. MEPERIDINE (DEMEROL) IS A NARCOTIC WITH A HIGH POTENTIAL FOR PHYSICAL AND
PSYCHOLOGICAL DEPENDENCY. UNDER WHICH CLASSIFICATION DOES THIS DRUG FALL?
A. I
B. II
C. III
D. IV
ANS: B
MEPERIDINE (DEMEROL) IS A SCHEDULE II DRUG; IT HAS A HIGH POTENTIAL FOR ABUSE
AND MAY LEAD TO SEVERE PSYCHOLOGICAL AND PHYSICAL DEPENDENCE. SCHEDULE I
DRUGS HAVE HIGH POTENTIAL FOR ABUSE AND NO RECOGNIZED MEDICAL USE.
SCHEDULE III DRUGS HAVE SOME POTENTIAL FOR ABUSE. USE MAY LEAD TO LOW TO
MODERATE PHYSICAL DEPENDENCE OR HIGH PSYCHOLOGICAL DEPENDENCE. SCHEDULE
IV DRUGS HAVE LOW POTENTIAL FOR ABUSE. USE MAY LEAD TO LIMITED PHYSICAL OR
PSYCHOLOGICAL DEPENDENCE.
DIF: COGNITIVE LEVEL: COMPREHENSION REF: P. 5 OBJ: 2 NAT: NCLEXCLIENT
NEEDSCATEGORY: SAFE, EFFECTIVE CARE ENVIRONMENT TOP: NURSINGPROCESS STEP:
ASSESSMENT CON: PATIENT EDUCATION | ADDICTION | PAIN
8. WHAT WOULD THE FDA DO TO EXPEDITE DRUG DEVELOPMENT AND APPROVAL FOR
AN OUTBREAK OF SMALLPOX, FOR WHICH THERE IS NO KNOWN TREATMENT?
A. LIST SMALLPOX AS A HEALTH ORPHAN DISEASE.
B. OMIT THE PRECLINICAL RESEARCH PHASE.
, C. EXTEND THE CLINICAL RESEARCH PHASE.
D. FAST TRACK THE INVESTIGATIONAL DRUG.
ANS: D
ONCE THE INVESTIGATIONAL NEW DRUG APPLICATION HAS BEEN APPROVED, THE DRUG
CAN RECEIVE HIGHEST PRIORITY WITHIN THE AGENCY, WHICH IS CALLED FAST
TRACKING. A SMALLPOX OUTBREAK WOULD BECOME A PRIORITY CONCERN IN THE
WORLD. ORPHAN DISEASES ARE NOT RESEARCHED IN A PRIORITY MANNER.
PRECLINICAL RESEARCH IS NOT OMITTED. EXTENDING ANY PHASE OF THE RESEARCH
WOULD MEAN A LONGER TIME TO DEVELOP A VACCINE. THE FDA MUST ENSURE THAT
ALL PHASES OF THE PRECLINICAL AND CLINICAL RESEARCH PHASE HAVE BEEN
COMPLETED IN A SAFE MANNER.
DIF: COGNITIVE LEVEL: KNOWLEDGE REF: P. 8 OBJ: 6 NAT: NCLEXCLIENT
NEEDSCATEGORY: SAFE, EFFECTIVE CARE ENVIRONMENT TOP: NURSINGPROCESS STEP:
ASSESSMENT
CON: HEALTH CARE LAW | HEALTH CARE POLICY | INFECTION | CARE COORDINATION
9. WHICH STATEMENT IS TRUE ABOUT OVER-THE-COUNTER (OTC) DRUGS?
A. THEY ARE NOT LISTED IN THE USP NF.
B. A PRESCRIPTION FROM A HEALTHCARE PROVIDER IS NEEDED.
C. THEY ARE SOLD WITHOUT A PRESCRIPTION.
D. THEY ARE KNOWN ONLY BY THEIR BRAND NAMES.
ANS: C
OTC MEDICATIONS DO NOT REQUIRE A PRESCRIPTION. A VARIETY OF NAMES, BOTH
GENERIC AND TRADE, CAN BE USED FOR INDIVIDUAL DRUGS SOLD OTC. OTC DRUGS ARE
LISTED IN THE USP NF. PRESCRIPTION DRUGS REQUIRE AN ORDER BY A HEALTH
PROFESSIONAL WHO IS LICENSED TO PRESCRIBE, SUCH AS A PHYSICIAN, NURSE
PRACTITIONER, PHYSICIAN ASSISTANT, OR DENTIST.
DIF: COGNITIVE LEVEL: COMPREHENSION REF: P. 2 OBJ: 2 NAT:
NCLEXCLIENT NEEDSCATEGORY: PHYSIOLOGICAL INTEGRITY TOP: NURSINGPROCESS STEP:
PLANNING CON: PATIENT EDUCATION
10. WHICH IS THE MOST AUTHORITATIVE REFERENCE FOR MEDICATIONS THAT ARE
INJECTED?
A. PHYSICIANS’ DESK REFERENCE
B. HANDBOOK ON INJECTABLE DRUGS
